ARWR

Arrowhead Pharmaceuticals, Inc.

29.25 USD
-0.23 (-0.78%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Arrowhead Pharmaceuticals, Inc. stock is down -11.87% since 30 days ago. The next earnings date is Apr 30, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 45.83% of the previous 23 February’s closed higher than January. In the last 10 Unusual Options Trades, there were 4 PUTs, 6 CALLs. 50% of analysts rate it a buy.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
09 Jan 18:23 16 Feb, 2024 45.00 PUT 75 1
10 Jan 16:47 21 Jun, 2024 35.00 CALL 40 421
11 Jan 15:53 19 Jan, 2024 25.00 CALL 20 642
11 Jan 17:54 19 Jan, 2024 25.00 CALL 20 642
16 Jan 20:27 19 Jan, 2024 25.00 CALL 30 617
17 Jan 16:30 19 Jan, 2024 30.00 CALL 92 893
07 Feb 14:53 21 Jun, 2024 45.00 PUT 62 0
08 Feb 19:37 20 Sep, 2024 35.00 PUT 100 33
12 Feb 14:31 15 Mar, 2024 35.00 CALL 250 947
13 Feb 17:24 21 Jun, 2024 30.00 PUT 100 417

About Arrowhead Pharmaceuticals, Inc.

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the. treatment of liver diseases associated with alpha-1 antitrypsin deficiency. ARO is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce the production of apolipoprotein A.

  • HC Wainwright & Co.
    Thu Feb 8, 15:25
    buy
    confirm
  • Citigroup
    Wed Feb 7, 14:06
    hold
    confirm
  • RBC Capital
    Wed Feb 7, 11:53
    buy
    confirm
  • Morgan Stanley
    Wed Feb 7, 05:32
    hold
    confirm